ITRM | Iterum Therapeutics plc Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.0202 - 1.1201
52 Week Range	0.6220 - 2.5000
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	193,358
Average Volume	306,433
Shares Outstanding	22,706,000
Market Cap	24,261,361
Sector	Healthcare
Industry	Biotechnology
IPO Date	2018-05-25

Valuation
Profitability
Growth
Health
P/E Ratio	-0.58
Forward P/E Ratio	N/A
EPS	-1.83
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	14
Country	Ireland
Website	ITRM

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

ITRM's peers: AREC, ONTX, ADIL, DFFN, AEZS, TNXP, FBIO, EYEN, OCUP, GRTX, CTXR, JAGX, ACST, IBIO, FWBI, DRMA, REVB, PBLA, CFRX, VRCA, HOTH, VINC

*Chart delayed

Analyzing fundamentals for ITRM we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see ITRM Fundamentals page.

Watching at ITRM technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on ITRM Technicals page.